Drug Profile
Research programme: overactive bladder - Dynogen/Johnson & Johnson
Alternative Names: Overactive bladder research programme - Dynogen/Johnson & JohnsonLatest Information Update: 29 Dec 2009
Price :
$50
*
At a glance
- Originator Dynogen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development
- Developer Dynogen Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 12 Jan 2004 Preclinical trials in Overactive bladder in USA (unspecified route)